A Review of the Therapeutic Anti-tumour Potential of Cannabinoids

Canna Clinical TrialsLeave a comment

Cannabis sativa is a plant rich in more than 100 types of cannabinoids. Besides exogenous plant cannabinoids, mammalian endocannabinoids and synthetic cannabinoid analogues have been identified. Cannabinoid receptors type 1 (CB1) and type 2 (CB2) have been isolated and characterised from mammalian cells. Through cannabinoid receptor and non-receptor signalling pathways, cannabinoids show specific cytotoxicity against tumour cells, while protecting healthy tissue from apoptosis. Cannabinoids also display potent anticancer activity against tumour xenografts, including tumours that express high resistance to standard chemotherapeutics.

Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis

Canna Clinical TrialsLeave a comment

Cannabis-based medicines (CBMs) may offer relief from symptoms of disease; however, their additional cost needs to be considered alongside their effectiveness. We sought to review the economic costs and benefits of prescribed CBMs in any chronic illness, and the frameworks used for their economic evaluation. Prescribed CBMs are a potentially cost-effective add-on treatment for MS spasticity; however, this evidence is uncertain. Further investment in randomised trials with in-built economic evaluations is warranted for a wider range of clinical indications.

Parent use of cannabis for intractable pediatric epilepsy: Everyday empiricism and the boundaries of scientific medicine

Canna Clinical TrialsLeave a comment

Cannabis is an increasingly sought-after remedy for US children with intractable (biomedically uncontrollable) epilepsy. However, like other complementary-alternative medicine (CAM) modalities, and particularly as a federally illegal, stigmatised substance, it is unsanctioned by mainstream medicine. Parents are largely on their own when it comes to learning about, procuring, dispensing, and monitoring treatments. Exploring how they manage is crucial to better assist them. Implications for understanding the boundaries of science are explored, as are norms for parent agency as ill children’s care managers, radicalisation among people affected by contested illnesses, and the future of ‘medical marijuana.’

T.H. Seeds strain story S.A.G.E.: The Queen is back! Words & Pics: Green Born Identity – G.B.I.

Strain ReviewsLeave a comment

“If you love to smoke, grow S.A.G.E.!” – said famous cannabis scientist Robert Connell Clarke about S.A.G.E. twelve years ago when this strain came out. Well, not many, not to say no other, strains get such a testimony from the world’s leading cannabis expert, and Rob Clarke certainly wouldn’t have staked his good name for a mediocre strain.

Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis

Canna Clinical TrialsLeave a comment

Canada has the highest incidence of MS worldwide. Anecdotal evidence reveals that people with MS smoke, ingest or vaporise cannabis for a multiplicity of reasons. With the legal situation in relation to use currently in flux, we undertook a study investigating patterns of use amongst people with MS and their attitudes towards the drug.There is a wide acceptance of cannabis within the MS patient community. One in five people currently use the drug for reasons that differ between neuropsychiatry and neurology clinics. Use could potentially more than double if the drug were legalised.

Cannabinoids in treatment-resistant epilepsy: A review

Canna Clinical TrialsLeave a comment

Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequately powered placebo-controlled, randomized trials (RCTs) with cannabidiol (CBD), a cannabis derivative. Previously, information was limited to case reports, small series, and surveys reporting on the use of CBD and diverse medical marijuana (MMJ) preparations containing: tetrahydrocannabinol (THC), CBD, and many other cannabinoids in differing combinations. These RCTs have studied the safety and explored the potential efficacy of CBD use in children with Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS).